Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New treatment options to increase both the survival and quality of life of patients are urgently needed. This study reports on a new non-cannabinoid, non-psychoactive derivative of cannabis, termed FBL-03G, with the potential to treat pancreatic cancer.
A recent Harvard study on mice has demonstrated that flavonoids in cannabis could shrink pancreatic cancer tumors. In the study, 70% of the mice treated with the compound saw tumors reduced to almost nothing or disappearing altogether. The study, entitled “Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer” was […]
The post New Study Suggests Cannabis Flavonoids Could Shrink Pancreatic Tumors appeared first on CBD Testers.